Reduction of Eosinophilic Inflammation in the Airways: Tolerability

There were no significant differences between montelukast and placebo in the frequency of clinical and laboratory adverse effects. While 27 patients were receiving montelukast, 13 patients reported a total of 26 clinical adverse effects; in comparison, 15 of 28 patients reported a total of 30 clinical adverse effects while receiving placebo. Respiratory events, especially cold syndrome, were most commonly observed. Concerning laboratory test findings, 4 of 27 patients receiving montelukast experienced a total of five laboratory adverse effects compared with 5 of 28 patients who had a total of six laboratory adverse effects while receiving placebo there canadian family pharmacy . Three patients, including one who received only montelukast, were withdrawn from the study because of worsening of asthma before starting period 2.
In the present randomized, placebo-controlled crossover study, we investigated the potential antiinflammatory effects of 4 weeks of treatment with montelukast on sputum and peripheral blood eosinophils, and on airway responsiveness to histamine in patients with mild-to-moderate asthma, In addition, the clinical efficacy of montelukast was evaluated, Although treatment with montelukast but not placebo resulted in significant decreases in sputum and peripheral blood eosinophils, neither montelukast nor placebo significantly changed airway responsiveness to histamine, Furthermore, only montelukast significantly increased both morning and evening PEF compared with baseline values, There was no significant relationship between the increase in PEF and the decrease in sputum eosinophils after treatment with montelukast, suggesting that improvement of PEF was not solely dependent on the improvement of airway eosinophilia, Because this study involved a relatively small sample size and did not have adequate power, asthma symptoms did not show significant improvement with montelukast treatment,